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ABSTRACT: Right heart function is the main determinant of prognosis in pulmonary arterial
hypertension (PAH). At present, no treatments are currently available that directly target the right
ventricle, as we will demonstrate in this article.
Meta-analysis of clinical trials in PAH revealed that current PAH medication seems to have
limited cardiac-specific effects when analysed by the pump-function graph. Driven by the
hypothesis that ‘‘left’’ and right heart failure might share important underlying pathophysiological
mechanisms, we evaluated the clinical potential of left heart failure (LHF) therapies for PAH,
based on currently available literature.
As in LHF, the sympathetic nervous system and the renin–angiotension–aldosterone system are
highly activated in PAH. From LHF we know that intervening in this process, e.g. by angiotensin-
converting enzyme inhibition or b-blockade, is beneficial in the long run. Therefore, these
medications could be also beneficial in PAH. Furthermore, the incidence of sudden cardiac death
in PAH could be reduced by implantable cardioverter-defibrillators. Finally, pilot studies have
demonstrated that interventricular dyssynchrony, present at end-stage PAH, responded
favourably to cardiac resynchronisation therapy as well.
In conclusion, therapies for LHF might be relevant for PAH. However, before they can be
implemented in PAH management, safety and efficacy should be evaluated first in well-designed
clinical trials.
KEYWORDS: Adrenergic b-antagonists, artificial cardiac pacing, implantable defibrillators,
pulmonary heart disease, rennin-angiotensin system, right ventricular dysfunction
P
ulmonary arterial hypertension (PAH) is
characterised by excessive pulmonary
vascular remodelling, resulting in a
marked increase in right ventricular (RV) after-
load. The thin-walled, crescent-shaped right
ventricle in the normal situation needs to
remodel to a thick-walled, more spherical-shaped
high-pressure pump to overcome the often four-
fold increase in pressure in the case of PAH.
Eventually, the right ventricle is not able to cope
with the increase in load and right heart failure
develops [1, 2]. Despite the successful introduc-
tion of several new pulmonary-selective vaso-
dilating therapies in the last 10 yrs, the prognosis
of PAH patients remains poor [3, 4].
The relationship between RV afterload (mainly
determined by pulmonary vascular resistance
(PVR) and pulmonary arterial compliance [5])
and RV dysfunction is not straightforward.
Patients with systemic sclerosis associated-PAH
(relatively low load/low pressure) have a worse
prognosis compared with patients with idiopathic
PAH, whereas patients with PAH associated with
congenital heart disease (high load/high pressure)
have a relatively good prognosis [6]. Also in PAH,
mean pulmonary artery pressure (P¯pa) and PVR
are of limited prognostic value, while the strongest
predictors of survival are reflections of RV
(mal)adaptation to its increased load (cardiac
index, right atrial pressure, tricuspid annular plane
systolic excursion and N-terminal pro-brain
natriuretic plasma levels) (fig. 1) [8–10]. Thus, it
is not the load per se, but the failing right ventricle
itself that leads to death.
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Current PAH medication (prostacyclines, endothelin receptor
blockers, phosphodiesterase (PDE)-5 inhibitors and calcium
antagonists) focuses on controlling the excessive vascular
remodelling typical for PAH, resulting in a reduction in RV
load [11]. Their cardiac-specific effects on RV adaptation and
remodelling have not really been studied yet, but they are most
probably of limited clinical relevance as we will demonstrate
later. Therefore, there is still unexploited potential for therapies
that directly target the right ventricle [12].
In left heart failure (LHF) it is well accepted that the process of
cardiac remodelling itself, regardless of the initial cardiac
event, is, although compensatory at first, detrimental in the
long run [13]. There is now convincing evidence that
intervening in the process of remodelling importantly reduces
morbidity and mortality in patients with LHF [14, 15]. We
hypothesise that the RV remodelling observed in PAH patients
shares important pathophysiological mechanisms with the
cardiac remodelling observed in LHF patients. This implies
that the adverse RV remodelling could possibly be treated with
the same well-established therapies for LHF.
To get better insight into the processes involved, it is essential
to clinically distinguish cardiac-specific effects of treatment
from their effects on load (pulmonary vasodilation), which also
indirectly affect the heart. Therefore, in the first part of this
review we will discuss how this separation of effects can be
studied, and will evaluate the cardiac-specific effects of current
PAH treatments. In the second part of the review we will
explore the potential relevance of current evidence-based LHF
therapy (table 1) for right heart failure secondary to PAH.
HOW CAN WE DISTINGUISH THE CARDIAC-SPECIFIC
EFFECTS OF PAH THERAPY FROM THE PULMONARY
VASODILATING EFFECTS?
The right ventricle and the pulmonary vascular bed are
functionally coupled [1, 2]. As a result, it is difficult to
distinguish cardiac-specific effects from pulmonary-specific
effects of an intervention with the use of standard diagnostic
tools (i.e. right heart catheterisation or echocardiography). For
example, bosentan treatment has been shown to partially
restore cardiac dimensions and function: compared with
placebo, bosentan treatment improved cardiac output
(0.4 L?min-1?m-2, p,0.01) and RV/left ventricular (LV) dia-
stolic area ratio (-0.64, p,0.01) [16]. However, these effects
are most probably the result of the decrease in RV load
(difference in PVR reduction, bosentan treatment versus
placebo: -415¡99 dyn?s?cm-5; p,0.001) [17] and are, therefore,
not cardiac specific. Similar observations have been reported
for epoprostenol, sildenafil and after successful pulmonary
endarterectomy or lung transplantation.
In an experimental setting, this problem can be circumvented
by using models with a fixed RV afterload (e.g. pulmonary
arterial banding). Herein we describe two methods that are
also applicable in a clinical setting.
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FIGURE 1. Haemodynamic changes during the progression of pulmonary
arterial hypertension (PAH). The continuous rise in pulmonary vascular resistance
(PVR) during the progression of PAH is initially compensated by concentric
remodelling of the right ventricle (RV). Right atrial pressure (Pra) remains normal and
there is a steep increase in mean pulmonary artery pressure (P¯pa) as cardiac index
(CI) at rest is preserved. In the next stage, the RV is not able to fully compensate for
the further increase of PVR and starts to decompensate; eccentric RV remodelling
is observed. There is a modest rise in P¯pa as CI also starts to fall. At this stage Pra
remains at near normal levels. In the final stage of overt right heart failure there is a
severe drop in CI, a steep rise in Pra and, even though PVR still increases, P¯pa drops
due to the low output state. Changes in RV function fit to the different disease
stages in PAH and explain the prognostic importance of CI and Pra over P¯pa. In
systemic sclerosis associated-PAH (?-?-?-), the ability of the RV to adapt to the
increasing PVR appears limited, therefore, the heart fails at lower PVR [7]. The aim
of specific RV-therapies (- - - -) is to improve the ability of the heart to adapt to its
afterload. Ref.: reference/normal value.
TABLE 1 Summary of current left (systolic) heart failure therapy
1. Treat underlying cause when possible, e.g. coronary artery disease and arterial hypertension
2. General measurements, self-care management (avoid drugs that adversely affect the clinical status whenever possible)
3. Diuretics (and moderate salt restriction)
4. b-blockers (initiated in very low doses, followed by gradual increment)
5. Angiotension-converting enzyme inhibitors (or angiotensin II receptor blockers, if intolerant for angiotension-converting enzyme inhibitors)
6. Aldosterone antagonists (only when renal function is preserved and closely monitored)
7. Exercise training (adjunct to optimal medical therapy)
8. Implantable cardioverter-defibrillator (patients at high-risk for life-threatening arrhythmic disorders)
9. Cardiac resynchronisation therapy (symptomatic heart failure patients despite optimal medical treatment, with signs of cardiac dyssynchrony):
digoxin, hydrazaline/nitrate, left ventricle assist devices, heart transplantation
The therapies marked in bold are not standard in current pulmonary arterial hypertension management. Data taken from [14, 15].
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Pressure–volume relationship
It is well accepted that from combined ventricular pressure
and volume measurements, parameters of cardiac function and
contractility can be derived that are independent of the arterial
load. An example of a load-independent parameter of systolic
function is the end-systolic elastance (Ees or Emax), which is
measured by the slope of the fitted line connecting end-systolic
pressure volume points (fig. 2b). In addition, load-indepen-
dent parameters of diastolic function can be derived [21, 22].
This method has been used successfully in describing LV
performance in multiple disease conditions [23], and more
recently its use has been validated in PAH patients for the right
ventricle as well [24]. The construction of pressure–volume
loops requires simultaneous measurements of instantaneous
pressure- and volume-signals (fig. 2a and b), which can only
be obtained using specialised equipment (e.g. conductance
catheters). Moreover, to accurately determine Ees, it is
necessary to vary cardiac load (usually by a temporary partial
occlusion of the inferior vena cava), which might be unac-
ceptable in patients that are haemodynamically compromised,
such as PAH patients. Fortunately, mathematical techniques
(e.g. single-beat estimation) have been developed that allow
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FIGURE 2. Distinguishing cardiac-specific from pulmonary-specific effects in pulmonary hypertension (PAH) patients. a) Pressure curves of the right ventricle (RV) and
the main pulmonary artery are shown. Maximal isovolumic pressure is estimated (Piso) by sine wave fit [18]. b) Pressure–volume loops can be constructed from instantaneous
pressure and volume measurements by use of conductance catheters. End-systolic elastance (Ees) is considered a load-independent measure of RV contractility and is
measured from the slope of the connecting line between end-systolic pressure (Pes) and Piso [19]. c) Increase in contractility. d) Decrease in pulmonary vascular resistance
(PVR). An alternative approach for describing heart function is the pump-function graph [20]. Here, average RV pressure versus stroke volume (SV) at steady state are plotted
(the working point) and by the same single-beat estimation (P¯iso), a pump-function graph is constructed (–––––). The slope of the line from the origin through the working point
is a measure for PVR divided by heart period (PVR/T) and, therefore, a measure for RV afterload. When RV contractility increases (c), this is observed in the pump-function
graph by increased P¯iso while SVmax remains unchanged; the new working point has moves to the upper right (#). When RV afterload is reduced (PVR/T decreases; d), the
pump-function graph remains unchanged, while the new working point moves to the lower right ("). P¯: mean pressure; Ppa: pulmonary artery pressure; PRV: RV pressure curve.
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reasonable estimation of Ees and only require a high-quality
RV pressure curve and a reliable stroke volume (SV)
measurement during steady state [18, 19]. Recent studies that
compared the separate cardiac and pulmonary effects of
norepinephrine, dobutamine and levosimendan in an experi-
mental model for right heart failure are examples of the
usefulness of the pressure–volume relationship (including
single-beat estimation) [25, 26].
Pump-function graph
An interesting alternative for studying cardiac-specific versus
pulmonary-specific effects is the pump-function graph [20, 22].
A major advantage of this method is that only instantaneous
pressure and average flow measurements suffice, and that its
analysis does not require instantaneous volume signals.
Average RV pressure is plotted against SV (the working point)
and, using the same single-beat estimation as discussed above,
a pump-function graph can be constructed (fig. 2c and d). An
increase in mean isovolumic pressure while SVmax remains
unchanged (fig. 2) indicates improved cardiac contractility: in
this case the new working point moves to the upper right
(fig. 2c). A change in cardiac load has a different effect: when
load decreases by pulmonary vasodilation (and cardiac
contractility remains unchanged) the working point moves to
the lower right. With the use of the pump-function graph, we
recently demonstrated lower cardiac contractility in systemic
sclerosis-associated PAH compared with idiopathic PAH,
which could well explain the patients’ worse prognosis despite
lower PVR [7].
When studying chronic (as opposed to acute) effects of an
intervention, both methods (pressure–volume loops and pump-
function graph) may be insufficient due to RV remodelling.
However, they can be further refined by incorporating measures
of RV remodelling (RV wall thickness and RV diameter) in the
analysis, in which case RV wall stress (s; estimated by Laplace’s
law) is used instead of RV pressure [22]. We conclude that by an
integral approach, it is certainly possible to distinguish the
cardiac-specific from the pulmonary-specific effects of an
intervention in PAH patients [22].
Often, it is very difficult to distinguish the cardiac- from the
pulmonary-specific effects of PAH therapy in patients. For this
purpose, the pressure–volume loop and the pump-function
graph have been developed. We propose the use of the pump-
function graph over the pressure–volume loop as it is more
easily obtained in patients using routine RV catheterisation.
CARDIAC EFFECTS OF CURRENT PAH MEDICATION
The cardiac-specific effects of current PAH therapies, in
contrast to their pulmonary-vasodilating effects, have only
been investigated in a small number of studies. The few
relevant experimental studies are discussed first.
Experimental studies
ZIERER et al. [27] investigated the effects of diltiazem (a calcium-
channel blocker) on RV function in a chronic model of RV
pressure overload, using pressure–volume analysis.
Administration of diltiazem during constant RV afterload
acutely depressed cardiac output, and this was mainly related
to depressed right atrial function and RV filling. KERBAUL et al.
[28] investigated the effects of prostacyclines in an acute model
of RV pressure overload, also using pressure–volume analysis.
Epoprostenol improved cardiac output, and this was explained
by a marked decrease in RV afterload without detectable
changes in RV contractility. These observations have been
confirmed by REX et al. [29]. Two recent papers studied the
effects of chronic treatment of sildenafil in a model where RV
pressure overload was induced by pulmonary artery banding
[30, 31]. Both studies reported an increase in RV hypertrophy
and/or improvement of RV function, which implies that there
is a direct effect of sildenafil on the heart. Prior to this,
NAGENDRAN et al. [32] reported upregulation of PDE-5 in
hypertrophied, but not in normal, rat and human RV
myocardium and also demonstrated acute inotropic effects of
sildenafil in the isolated Langendorff-perfused heart. In
summary, experimental data suggest acute detrimental effects
of calcium-channel blockers, a neutral effect of prostacyclines
and possibly beneficial cardiac-specific effects of sildenafil on
RV function and RV remodelling. Currently, no (experimental)
data is available on the cardiac-specific effects of endothelin
receptor blockers on the right ventricle in the setting of PAH.
To date, these substances have only been evaluated in models
in which RV afterload was not fixed.
Meta-analysis of clinical studies
To the best of our knowledge, no clinical studies exist that
specifically separated the cardiac from pulmonary effects of
current PAH therapies. Therefore, we re-evaluated all placebo-
controlled randomised clinical trials in PAH that included
serial invasive haemodynamic data, recently summarised by
GALIE et al. [33], by use of the pump-function graph (fig. 3). P¯pa
was used as a surrogate measure for mean RV pressure, SV
indexed for body surface area (SVi) was recalculated by
dividing cardiac output by heart rate and body surface area
(estimated as 1.82 m2 if not reported). Concomitant evaluation
of the haemodynamic changes in P¯pa and SVi by the pump-
function graph, during a typical study period of 12 weeks
(range 8 weeks to 12 months), suggests that current PAH
therapies have predominantly pulmonary vasodilating effects.
This is highlighted by comparing figure 3 with the situation in
figure 2d. Although future clinical studies specifically designed
to address this issue are necessary, this observation demon-
strates that there is a strong rationale for developing novel PAH
therapies that specifically target the right ventricle [12].
Right heart function is the main determinant of prognosis in
PAH. Current medication (endothelin receptor blockers, PDE-5
inhibitors and prostacyclines) appears to have limited cardiac-
specific effects (when analysed by an RV pump-function
graph). Novel therapies that specifically improve right heart
function in PAH are needed.
RELEVANCE OF LHF THERAPIES FOR PAH-RELATED
RIGHT HEART FAILURE
The cornerstones of current (systolic) LHF therapy are:
(loop)diuretics; a b-blocker; and angiotensin-converting
enzyme (ACE) inhibitors, or angiotensin II receptor blockers
if ACE inhibitors are not tolerated (table 1). In case of
persisting symptoms, an aldosterone antagonist or an angio-
tensin blocker is added, if the patient’s renal function permits.
Exercise training is regarded an adjuvant therapy. For selected
LHF patients, an implantable cardioverter-defibrillator and/or
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cardiac resynchronisation therapy can be considered. These
therapies are well-established and are based on numerous
well-designed randomised controlled trials (more details on
current LHF therapy can be found in current guidelines [14,
15]). Of note, clinical benefit in these trials was demonstrated
irrespective of the aetiology of LHF. This supports the current
idea that the process of cardiac remodelling, after the initial hit,
is similar and independent of its cause (e.g. ischaemia or
hypertension) [13]. However, it has been argued that therapy
efficacy might be different in systolic versus diastolic heart
failure (different LHF phenotype) [34]. Therefore, as the
cardiac remodelling observed in PAH patients with right heart
failure is comparable to that of systolic LHF (reduced ejection
fraction and ventricular dilatation) [10], only these recommen-
dations will be discussed in this article.
It is tempting to extrapolate the LHF recommendations to right
heart failure, even though there are important structural,
functional and developmental differences between the left and
right ventricle [1, 2]. Nevertheless, there is already some
overlap in recommendations between the LHF and PAH
guidelines [3, 4, 14, 15], which suggests that, at least from a
therapeutic perspective, there might be some interesting
similarities. For example, loop diuretics are widely used to
achieve fast symptomatic relief, both in PAH as well as in LHF.
In addition, nowadays, moderate exercise training is accepted
as an adjuvant therapy for PAH patients that are clinically
stable and under optimal medical treatment [35–37].
Since loop diuretics and exercise training are already part of
the recommendations of current PAH guidelines, we will not
discuss these therapeutic modalities any further here. We will
also not discuss therapies for LHF that are still experimental.
Instead, this review will focus on the clinical potential of: 1) b-
blockers as modulators of the sympathetic nervous system;
2) ACE inhibitors, angiotensin blockers and aldosterone
antagonists as modulators of the renin–angiotensin–aldoster-
one system (RAAS); and 3) the potential of electrical cardiac
interventions, such as implantable cardioverter-defibrillators
and cardiac resynchronisation therapy, as novel add-on
therapies for PAH (fig. 4). Because there are hardly any
prospective controlled data available that investigated the
relevance of these LHF therapies in PAH, we will mainly focus
on the relevance of the underlying pathophysiological
mechanisms for PAH that are affected by these interventions.
NEUROHUMORAL ACTIVATION AND PAH
The combined use of a b-blocker (more specifically bisoprolol,
carvedilol or sustained released metoprolol) with either an
ACE inhibitor, angiotensin blocker and/or an aldosterone
antagonist, in addition to symptomatic treatment by loop
diuretics, significantly reduces morbidity and mortality in LHF
[14, 15]. These medications modulate the underlying ‘‘neuro-
humoral activation’’, which is nowadays considered patholo-
gical in the long run, as they promote cardiac remodelling and
progression of the disease [13, 38]. Neurohumoral activation in
LHF can be seen as a state in which neural and hormonal
systems designed to maintain adequate organ perfusion are
increased to excessively high levels. This activation includes
many components, of which the sympathetic nervous system
and RAAS are, from a therapeutic perspective, the most
relevant [14, 15, 38].
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FIGURE 3. Meta-analysis of pulmonary arterial hypertension (PAH) trials by
pump function. Each arrow shows the general absolute change in indexed stroke
volume (DSVi) and mean pulmonary artery pressure (DP¯pa; as a surrogate measure
for mean right ventricle pressure) per study group of all placebo controlled
randomised clinical trials in PAH reporting serial haemodynamic measurements
[33]. A decrease in SVi was always accompanied by an increase in P¯pa in the
placebo group (red arrows), implying an increase in pulmonary vascular resistance
(PVR) without relevant changes in cardiac contractility. For the intervention groups
(blue arrows), an increase in SVi was always accompanied by a decrease in P¯pa,
implying reduction in PVR without important changes in cardiac contractility.
Therefore, current PAH medications predominantly have pulmonary vasodilating
effects with only limited cardiac-specific effects.
ETRAs
PDE-5 inhibitors
Prostacyclines
PAH:
↑RV afterload
Diuretics Overfilling Dyssynchrony CRT
↓RV function
↓Cardiac output
SNS RAASβ-blockersDigoxin
ACEIs
ARBs
Aldo ant
↑Norepinephrine, ↑MSNA 
↓123I-MIBG, ↓HRV 
RV βAR downregulation
↑Renin, ↑angiotensin II 
Hyponatriaemie 
RV AT1R downregulation
RV remodelling
Progression of RHF Ventricle arthythmias ICD
FIGURE 4. Schematic diagram showing as yet unexplored pathophysiological
mechanisms in pulmonary arterial hypertension (PAH). RV: right ventricular; ETRAs:
endothelin receptor antagonists; PDE-5: phosphodiesterase-5; CRT: cardiac
resynchronisation therapy; SNS: sympathetic nervous system; RAAS: renin–
angiotensin–aldosterone system; ACEIs: angiotensin-converting enzyme inhibitors;
ARBs: angiotension receptor blockers; MSNA: muscle sympathetic nervous activity;
HRV: heart rate variability; bAR: cardiomyocyte b1-adrenergic receptor; AT1R:
cardiomyocyte angiotensin type 1 receptor; Aldo ant: aldosterone antagonist; RHF:
right heart failure; ICD: implantable cardioverter defibrillator.
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Sympathetic nervous system
Autonomic dysbalance with dominance of the sympathetic
system already occurs at early stages of LHF [39], and is
mainly attributed to reduced baroreceptor discharge.
Baroreceptors, mainly located in the aortic arch, carotid
arteries and the left ventricle, are normally triggered by
mechanical stretch and respond by tonically inhibiting the
central sympathetic neural outflow. In the case of LHF, both
systemic arterial pressures and baroreceptor sensitivity are
reduced. Sympathetic overdrive leads to chronically elevated
levels of norepinephrine, resulting in overstimulation and
selective downregulation of the cardiac-specific b1-adrenergic
receptors in the left ventricle. This stimulus not only leads to
increased cardiac mechanical stress (by inotropic, chronotropic
and vasoconstrictive effects), but also has direct cardiotoxic
effects [40]. As a result, LV remodelling progresses with
further functional deterioration [38]. b-blockers are able to stop
this vicious circle of heart failure by antagonising the b-
adrenergic receptor [41]. Of interest, the therapeutic effects of
digoxin are no longer solely attributed to its weak inotropic
effects, but also to its modest neurohumoral effects: digoxin
indirectly sensitises the cardiac baroreceptor, and in this way
reduces sympathetic outflow of the central nervous system [42].
Although sympathetic activity is difficult to measure in the
clinical setting, several methods have been developed to
demonstrate sympathetic overdrive in LHF patients [39]. Of
these, measurements of regional norepinephrine spill-over or
microneurography (which directly measures post-ganglionic
muscle sympathetic nerve activity (MSNA)) quantify sympa-
thetic activity best. A sophisticated noninvasive alternative is
the use of 123I-MIBG tracers (heart-to-mediastinum ratio falls
when the sympathetic nervous system is chronically activated).
A cruder but easy method is the assessment of heart rate
variability (which is reduced when the sympathetic nervous
system is over-activated).
Renin–angiotensin–aldosterone system
Another relevant system in this context, closely interrelated
with the sympathetic nervous system, is the RAAS [43]. This
system is triggered by impaired renal perfusion due to reduced
cardiac output. In this case, the juxtaglomular cells in the
kidneys react by secreting renin. Renin increases angiotensin I
levels, from which angiotensin II is formed by ACE (abun-
dantly present in the lung endothelium). Angiotensin II
mediates multiple processes: it is a potent vasoconstrictor
and it has inotropic, natriuretic and antidiuretic properties. In
the setting of LHF, all impose cardiac stress and are
detrimental in the long run. Like norepinephrine, elevated
levels of angiotensin II over stimulate and selectively down-
regulate its angiotensin II type 1 (AT1)-receptor in the left
ventricle, directly promoting cardiac remodelling. Furthermore,
angiotensin II stimulates the secretion of aldosterone as well as
vasopressin (also called antidiuretic hormone). Both have
natriuretic and antidiuretic effects and also directly promote
cardiac remodelling. ACE inhibitors, angiotensin blockers and
aldosterone antagonists interfere in this process by suppressing
specific components of RAAS [14, 15].
RAAS activity is relatively easily quantified by directly
measuring renin or angiotensin II activity in plasma. A simple
but indirect alternative to measure chronically activated RAAS
is the assessment of hyponatremia [38].
Over-activation of the sympathetic nervous system in PAH
Since the primary trigger of neurohumoral activation in LHF
(reduction in cardiac output) is also an important clinical
feature in PAH, one would expect that the sympathetic
nervous system and RAAS are highly activated in PAH as
well. Indeed, measurements of the sympathetic and RAAS
activation in PAH are comparable to those in LHF [44, 45].
Measurements in PAH patients, as in LHF, revealed elevated
levels of norepinephrine in plasma [46, 47], although this was
not consistently found in other studies [48]. Furthermore,
increased MSNA [48] reduced cardiac uptake of 123I-MIBG
[49], reduced heart rate variability [50], and selective down-
regulation the b1-adrenergic receptors in the right (but not left)
ventricle have been observed in PAH patients [51], which are
all indicators of increased sympathetic activity affecting the
right ventricle. Moreover, these findings were correlated with
disease severity.
RAAS is also involved in PAH-induced right heart failure.
FORFIA et al. [52] recently identified hyponatremia, which
indirectly indicates RAAS activation as an important indepen-
dent prognostic factor in PAH. Parameters that more directly
measure RAAS activation (increased renin activity, elevated
levels of angiotensin II, aldosterone and/or vasopressin) have
not been systematically investigated in PAH patients yet.
Nevertheless, increased renin activity and elevated aldosterone
levels in plasma have been demonstrated in patients with right
heart failure due to hypoxic pulmonary hypertension (cor
pulmonale) [53], and in different experimental models of PAH-
induced right heart failure [54]. In addition, selective down-
regulation of the AT1-receptor in the right ventricle has been
observed in PAH patients [55].
Taken together, these studies suggest that the sympathetic
nervous system and RAAS are highly activated in PAH. But in
contrast to LHF, there are only a few clinical studies that have
explored the therapeutic potential of neurohumoral modula-
tion. RICH et al. [56] investigated the effect of i.v. administration
of digoxin in PAH patients and found acute improvement in
cardiac output with concomitant reduction in norepinephrine
levels, comparable to the digoxin effect in LHF.
Interestingly, no clinical trial exists in PAH-induced right heart
failure on the effects of b-blockers, which have more potent
effects on the sympathetic nervous system than digoxin. By
common clinical consensus, b-blocker use is even contra-
indicated. Often this is substantiated by the study of
PROVENCHER et al. [57]. They reported significant functional
improvement, 2 months after b-blocker withdrawal in a small
series of patients with porto-pulmonary hypertension.
However, all patients (treated for prophylaxis of variceal
bleeding) were receiving high-dose propanolol or atenolol.
These old b-blockers are also contraindicated for LHF because
of their profound myocardial depressive and vasoconstrictive
effects, in comparison to newer b-blockers [41]. Moreover, it is
well-known from LHF that acute functional improvements do
not invariably lead to favourable changes long-term, and that
overall beneficial effects of b-blockers can typically be expected
after chronic use of o3 months [41].
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Another (related) argument against b-blocker use in PAH is the
importance of maintenance of RV systolic function. Acute
administration of a b-blocker is known to exacerbate dyspnoea,
most likely due to its negative inotropic effects, leading to
instant ventriculo-arterial uncoupling [18]. However, this
temporary effect might be better tolerated by careful use of
selective b-blockers (‘‘start low, go slow’’), as is successfully
demonstrated in LHF-patients [14, 15].
Although this is against present consensus, we would like to
argue that, like in LHF, the sympathetic nervous system is
activated to pathological levels in PAH, and that this could be
normalised by careful b-blocker use. Further (pre-clinical)
research is necessary to investigate whether a low-dose of a
newer selective b-blocker might be a tolerable option to abolish
the detrimental effects of sympathetic overdrive in PAH.
Activation of RAAS in PAH
RAAS has long been recognised to play an important role in
pulmonary vascular remodelling and pulmonary vasoconstric-
tion [58, 59]. Therefore, when captopril (the first ACE inhibitor)
became commercially available, this new drug was eagerly
tested in PAH patients, for whom no effective treatment
existed at that time. In the 1980s, four small case-series (26
patients in total) reported on the haemodynamic effects of
captopril in PAH. Three of the studies were positive and found
a significant increase in cardiac output [60, 61] and exercise
capacity [62]. One study, however, did not observe any
haemodynamic changes, neither positive nor negative [63].
Surprisingly, no additional clinical studies have been pub-
lished since. Currently, there is renewed interest in RAAS since
the discovery of ACE2, an isoform of ACE with counteractive
(protective) actions [64, 65]. The theoretical beneficial effects of
ACE inhibitors, angiotensin blockers and/or aldosteron
antagonists on the heart in PAH have not been addressed in
patients yet.
Pre-clinical studies using different models of PAH and right
heart failure, however confirmed that the use of ACE inhibitors
or angiotensin blockers significantly reduces RV remodelling
and improves cardiac function and/or survival [66–69]. We
conclude that in PAH, pharmacological interference in RAAS
could (partially) reverse pulmonary and cardiac remodelling,
which warrants a prospective controlled clinical study of the
effects of ACE inhibitors, angiotensin blockers and/or aldos-
terone antagonists.
There is convincing evidence that, as in LHF, the sympathetic
nervous system and RAAS in PAH are highly activated. Well-
established pharmacological interventions for LHF could,
therefore, be relevant for PAH as well. However, ACE
inhibitors, angiotensin II blockers and selective b-blockade
have not been explored in PAH, and clinical investigations of
the potential of these drugs are urgently needed. Nevertheless,
routine use of these neurohumoral modulators and, in
particular, the use of b-blockers are currently not recom-
mended in PAH, unless future studies can prove that their use
in PAH is safe and beneficial.
ELECTRICAL REMODELLING AND PAH
Implantable cardioverter-defibrillators and cardiac resynchron-
isation therapy are relatively new therapeutic modalities in LHF
management. Major heart failure guidelines contain recommen-
dations on implantable cardioverter-defibrillator use since 2001,
but recommendations on resynchronisation therapy have only
been incorporated since 2005. For selected LHF patient groups, it
is now well-accepted that resynchronisation therapy signifi-
cantly reduce morbidity, and both cardioverter-defibrillators
and resynchronisation therapy significantly reduce mortality, in
addition to the beneficial effect of optimal pharmacological LHF
treatment [14, 15].
Implantable cardioverter-defibrillator
A cardioverter-defibrillator detects and prematurely termi-
nates malignant and life-threatening ventricular arrhythmias,
preventing sudden cardiac death. The incidence of ventricular
arrhythmias increases with the progression of LHF. Therefore,
implantable cardioverter-defibrillator use is currently recom-
mended as secondary prevention for sudden cardiac death in
LHF patients with a (presumed) history of ventricular
arrhythmia, or as primary prevention in LHF patients with a
severely reduced left ventricular-ejection fraction. In both cases
LHF patients must have a reasonable expectation of survival
with acceptable functional status of .1 yr [14, 15]. The clinical
trials, on which these recommendations are based, reported a
relative reduction of all-cause mortality after 24 months of
,30% and an absolute risk reduction of ,5% [70, 71], which
implies a number-needed-to-treat of ,20 patients.
Also in PAH, sudden cardiac death, presumably due to
malignant ventricular arrhythmias, has been recognised as an
important clinical risk for these patients [72]. As in LHF,
markers for an ‘‘electrically instable heart’’, such as prolonged
QTc-intervals and increased QT dispersion derived by ECG
[73], neurohumoral disturbances (as discussed previously) and
increase in cardiac fibrosis [74], have been demonstrated in
PAH patients. However, in contrast to LHF, the actual
incidence of events related to ventricular arrhythmias in
PAH is considered to be low. However, the reported
percentages of deaths in PAH attributed to ventricular
arrhythmias vary widely, from 8 to 26% [8, 75], and the actual
numbers might importantly differ for the different PAH
subgroups (e.g. higher for PAH associated with congenital
heart disease, which might be related to the presence of
surgical cardiac scars [76]). Moreover, these numbers are based
on retrospective studies and were partially obtained before the
introduction of PAH specific medications. Systematic prospec-
tive clinical studies are necessary to accurately determine the
current incidence of sudden cardiac deaths in different
subgroups of PAH. These data will allow a crude estimation
of the clinical potential of cardioverter-defibrillators in PAH,
by calculation of the number-needed-to-treat (extrapolating the
effect of cardioverter-defibrillators in LHF). Until then,
implantable cardioverter-defibrillators (or pharmacological
anti-arrhythmic agents) are generally not recommended as a
(primary) preventive measure for sudden cardiac death in
PAH patients [4, 72].
Supraventricular tachyarrhythmias
In contrast to ventricular arrhythmias, the incidence of
supraventricular arrhythmias seems to be much higher, and
they are considered to be an important cause of clinical
deterioration in PAH patients. In a retrospective analysis [77],
REVIEW: POTENTIAL THERAPIES FOR RIGHT HEART FAILURE M.L. HANDOKO ET AL.
78 VOLUME 19 NUMBER 115 EUROPEAN RESPIRATORY REVIEW
an annual incidence of supraventricular tachyarrhythmias in
PAH of ,3% was found: atrial fibrillation and atrial flutter
were equally common. In this study, persistent atrial fibrilla-
tion was associated with a very poor prognosis (nine out of 11
PAH patients died within 24 months), which may be explained
by worsening of RV function due to the loss of atrial ‘‘kick’’ to
ventricular filling. Maintenance of sinus rhythm is, therefore,
currently considered an important treatment goal in PAH [4].
However, this is in contrast to the clinical experience in LHF.
The treatment strategy of rhythm-control, compared with rate-
control (which is acceptance of atrium fibrillation and lowering
of the ventricular response-rate in combination with adequate
anticoagulation), had no superior effect on survival, whereas it
required more hospitalisation because of the need for repeated
cardioversion [78, 79]. We fully support current recommenda-
tions to restore and maintain sinus rhythm in PAH patients if
possible, by lack of prospective and controlled data. Future
trials, however, are necessary to test the validity of this
treatment strategy.
Cardiac resynchronisation therapy
Cardiac dyssynchrony in LHF is characterised by regional
differences in electrical and/or mechanical activation of the left
ventricle (usually a delay in activation of the LV free wall in
relation to the interventricular septum). Dyssynchrony results
in inefficient pumping of the left ventricle, and further clinical
deterioration. Cardiac resynchronisation therapy can acutely
restore synchrony of LV contraction, thereby improving
overall LV (systolic) performance. In the long run, resynchron-
isation therapy leads to reversed cardiac remodelling, resulting
in an even further improvement of LV performance. Although
the current clinical selection criteria for resynchron-
isation therapy (wide QRS complex on ECG) sub-optimally
predict clinical benefit for the individual LHF patient,
resynchronisation therapy has been shown to significantly
reduce morbidity and mortality, and is now a well-established
treatment modality in LHF [14, 15].
Ventricular dyssynchrony is often also observed in progressive
stages of PAH-induced right heart failure [80, 81]. Mechanical
interventricular dyssynchrony in PAH (which is clinically easily
recognised by the paradoxical bulging of the interventricular
septum) is associated with impaired RV systolic function.
Furthermore, through septum bulging, ventricular dyssynchrony
is thought to impair LV diastolic function as well [82, 83].
Resynchronisation of the right ventricle could, therefore, be of
clinical benefit in PAH. However, we recently demonstrated that
LV and RV dyssynchrony are essentially different: the origin of
PAH-related ventricular dyssynchrony lies in regional differ-
ences in the duration of the contraction, rather than regional
differences in onset of the contraction (e.g. due to a conductance
delay); and is highly afterload dependent [83, 84].
Previously, successful application of cardiac resynchronisation
therapy has been demonstrated in patients with PAH
associated with congenital heart disease [85]. However, these
patients display a ‘‘LHF-like’’ dyssynchrony due to a complete
right bundle branch block as a (late) complication of cardiac
surgery and are, therefore, not representative for the PAH
population in general. We recently explored the clinical
potential of resynchronisation therapy in an experimental
model of PAH-induced right heart failure, in the absence of
conduction disturbances [84]. We found that pre-excitation of
the RV free wall resulted in improved RV systolic function and
reduced adverse LV diastolic interaction. Interestingly, these
findings have recently been confirmed by HARDZIYENKA et al.
[86] in a study with patients suffering from right heart failure
and ventricular dyssynchrony secondary to chronic thrombo-
embolic pulmonary hypertension. A cohort of 67 patients was
pre-operatively screened by standard tissue-Doppler echocar-
diography and seven patients were selected for a temporary
pacing protocol, based on the presence of large diastolic
interventricular delay (as a quantification of PAH-related
ventricular dyssynchrony). Resynchronisation therapy acutely
reduced ventricular dyssynchrony, enhanced RV contractility
and LV diastolic filling, and resulted in an improvement of SV
of .10%. These promising results warrant further investiga-
tions of cardiac resynchronisation therapy as a novel treatment
for right heart failure secondary to PAH [12], that should focus
on its long-term effects, and on the identification of robust
selection criteria for PAH patients that could profit most from
cardiac resynchronisation therapy.
In PAH, the incidence of malignant ventricular arrhythmias is
considered low, but this observation needs prospective
validation. For now, the use of implantable cardioverter-
defibrillators is not recommended for PAH patients.
Supraventricular tachyarrhythmias often lead to clinical
deterioration. Based on retrospective data, maintenance of
sinus rhythm is an important treatment goal, but this
preference of rhythm- over rate-control needs be confirmed
in prospective controlled studies, especially because this is
opposite to the experiences in left heart failure. Cardiac
resynchronisation therapy emerges as a promising new
treatment modality. Prospective controlled trials are necessary
to study its long-term effects and to identify robust selection
criteria.
CONCLUSIONS AND FUTURE DIRECTIONS
In this review we investigated the potential applicability of
current LHF therapy for the treatment of PAH-induced right
heart failure. Based on available literature, we conclude that:
LHF and right heart failure share important underlying
pathophysiological mechanisms that are amenable for treat-
ment (fig. 4); however, clinical experience with current LHF
treatments in the setting of PAH is very limited.
This discrepancy is intriguing, and we can only speculate
about its reasons. First, it is difficult to separate cardiac- from
pulmonary-specific effects of therapeutic interventions in PAH
patients. As a solution, we propose the use of the pump-
function graph. Secondly, PAH remains a rare disease where
many other clinical trials have been undertaken in the last two
20 yrs [33]. Thirdly, until recently right heart failure was
regarded as an inevitable final consequence of PAH, whereas it
s now the right ventricle which is considered a potential
therapeutic target [12].
So, how do we move forward? Solid clinical evidence is
essential before LHF therapy can be implemented in PAH
management. Therefore, phase I/II trials need to be conducted
first, which must provide insights in safety, tolerability and
efficacy of LHF therapy in PAH. Subsequently, randomised
clinical trials should be performed that compare current PAH
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therapy with and without add-on LHF therapy. An important
aspect is sufficient duration of the trial: the experiences in LHF
would predict that reversal of cardiac remodelling requires
more than the typical 12-week trial duration. In addition, the
question remains as to which end-point to choose in these
types of studies: classical end-points in PAH trials, such as 6-
min walking distance, might not be sensitive enough, and
direct measures for RV remodelling and function are possibly
more appropriate. However, the most ideal end-point, mortal-
ity, might be too stringent and will require inclusion of
unrealistically high numbers of patients [87].
To conclude, well-designed clinical studies are warranted, as
they might provide supporting evidence for the use of novel
therapeutic modalities that are relatively easily available to
treat this devastating disease. Future investigations will reveal
whether going ‘‘left’’ is a step in the ‘‘right’’ direction.
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